The Survival of Patients with Triple Negative Breast Cancer Undergoing Chemotherapy Along With Lifestyle Change Interventions

Background: The survival of patients with triple-negative breast cancer subtype undergoing chemotherapy along with weight management, physical activity, and diet was examined. In addition, the relationship between the Overall Survival (OS) of patients and the expression of P۵۳ and Ki ۶۷ was investigated. Methods: The study was conducted on ۱۱۰ patients admitted to oncology clinics between October ۲۰۰۹ and July ۲۰۱۸. The patients underwent five chemotherapy cycles, including Docetaxel, Epirubicin, and Cyclophosphamide once every ۲۱ days followed by two cycles of Epirubicin, Cyclophosphamide, and ۵-Fluorouracil. The patients also received guidelines for physical exercise, diet, and lifestyle change. Results: The median and mean follow-ups were ۵۲.۳ and ۴۵.۶ months respectively. Eight patients were metastatic and ۱۰۳ were under adjuvant therapy, ۱۳ of whom had relapses. The median relapse-free survival and mean OS were ۴۴.۴ months and ۴۹.۲ months, respectively. OS for P۵۳-negative patients was ۶۴.۲ months, eight patients relapsed in the P۵۳-positive group, and two relapsed in the P۵۳-negative group. Survival was more favorable in the negative group (P=۰.۰۲۱). The mean DFS in the P۵۳-negative group was ۹۶.۱% and ۷۶.۳% in the P۵۳-positive group, suggesting a more favorable status in the P۵۳-negative group. Out of ۱۱۰ patients, ۲۰ died and ۹۰ are still alive. Conclusion: Combining physical exercise, diet, and lifestyle change with chemotherapy increases the chance of a better response to treatment and a reduction in the rate of relapse during the first three years. The survival rate was better in p۵۳-negative patients.